JANX
Janux Therapeutics Inc
NASDAQ: JANX · HEALTHCARE · BIOTECHNOLOGY
$14.37
+1.84% today
Updated 2026-04-30
Market cap
$882.06M
P/E ratio
—
P/S ratio
88.21x
EPS (TTM)
$-1.83
Dividend yield
—
52W range
$12 – $35
Volume
1.0M
Janux Therapeutics Inc (JANX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-3.83M | $-4.37M | $-16.98M | $-42.92M | $-50.58M | $-43.81M | $-82.23M |
| Capital expenditures | $1.48M | $1.48M | $1.48M | $6.45M | $1.85M | $359000.00 | $1.04M |
| Depreciation | $6000.00 | $13000.00 | $113000.00 | $841000.00 | $1.96M | $2.06M | — |
| Stock-based comp | $6000.00 | $72000.00 | $6.91M | $17.20M | $20.00M | $33.02M | $40.22M |
| Free cash flow | $-5.31M | $-5.85M | $-18.46M | $-49.37M | $-52.42M | $-44.17M | $-83.28M |
| Investing cash flow | $-340.96M | $-340.96M | $-340.96M | $58.27M | $-41.19M | $-258.02M | — |
| Financing cash flow | $4.00M | $11.52M | $386.52M | $500000.00 | $59.55M | $713.24M | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | $28.59M | $15.84M | — | — | — |